Merck and Moderna Report Positive Phase 3 INTerpath-001 Trial Results
Merck and Moderna announced positive recurrence-free and distant metastasis-free survival results for intismeran autogene plus Keytruda in the Phase 3 INTerpath-001 trial.
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ:MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismera…